Ginkgo Bioworks Holdings, Inc.
NYSE: DNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Kelly
- Employees
- 834
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $635.6M
- Website
- https://www.ginkgobioworks.com
Loading DNA…
Loading profile data…Frequently asked questions about DNA
What does Ginkgo Bioworks Holdings, Inc. (DNA) do?
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital...
Where does DNA trade?
Ginkgo Bioworks Holdings, Inc. (DNA) trades on the New York Stock Exchange.
What sector is DNA in?
Ginkgo Bioworks Holdings, Inc. (DNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ginkgo Bioworks Holdings, Inc.?
Jason Kelly is the chief executive officer of Ginkgo Bioworks Holdings, Inc. (DNA).
Where is Ginkgo Bioworks Holdings, Inc. headquartered?
Ginkgo Bioworks Holdings, Inc. is headquartered in United States.
Does DNA pay a dividend?
Ginkgo Bioworks Holdings, Inc. (DNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DNA go public?
Ginkgo Bioworks Holdings, Inc. (DNA) completed its initial public offering in 2021.